Aurisco Pharmaceutical Co., Ltd. (605116) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Aurisco Pharmaceutical Co., Ltd.

Why is Aurisco Pharmaceutical Co., Ltd. ?

Negative results in Mar 25

INTEREST(HY) At CNY 17.75 MM has Grown at 941.99%
DEBT-EQUITY RATIO (HY) Highest at 1.57 %
INVENTORY TURNOVER RATIO(HY) Lowest at 1.13%

With ROE of 16.35%, it has a fair valuation with a 3.61 Price to Book Value

Over the past year, while the stock has generated a return of 4.19%, its profits have risen by 4.6% ; the PEG ratio of the company is 4.8
At the current price, the company has a high dividend yield of 1.3

Underperformed the market in the last 1 year

The stock has generated a return of 4.19% in the last 1 year, much lower than market (China Shanghai Composite) returns of 14.77%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Aurisco Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Aurisco Pharmaceutical Co., Ltd. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Aurisco Pharmaceutical Co., Ltd.

6.98%

0.06

27.28%

China Shanghai Composite

15.19%

1.01

14.58%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

20.62%

EBIT Growth (5y)

27.33%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

0.01

Sales to Capital Employed (avg)

0.52

Tax Ratio

12.85%

Dividend Payout Ratio

32.54%

Pledged Shares

Institutional Holding

ROCE (avg)

17.19%

ROE (avg)

13.03%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.61

EV to EBIT

19.43

EV to EBITDA

15.94

EV to Capital Employed

3.57

EV to Sales

5.65

PEG Ratio

4.83

Dividend Yield

1.31%

ROCE (Latest)

18.39%

ROE (Latest)

16.35%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bearish

Sideways

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

ROCE(HY)

Highest at 17.43%

RAW MATERIAL COST(Y)

Fallen by -19.02% (YoY

NET SALES(Q)

Highest at CNY 399.2 MM

OPERATING PROFIT(Q)

Highest at CNY 136.75 MM

PRE-TAX PROFIT(Q)

Highest at CNY 139.94 MM

NET PROFIT(Q)

Highest at CNY 118.07 MM

EPS(Q)

Highest at CNY 0.3

-13What is not working for the Company

INTEREST(HY)

At CNY 17.75 MM has Grown at 941.99%

DEBT-EQUITY RATIO (HY)

Highest at 1.57 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.13%

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.44%

Here's what is working for Aurisco Pharmaceutical Co., Ltd.

Net Sales

Highest at CNY 399.2 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Operating Profit

Highest at CNY 136.75 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CNY MM)

Pre-Tax Profit

Highest at CNY 139.94 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 118.07 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.3

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Raw Material Cost

Fallen by -19.02% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Aurisco Pharmaceutical Co., Ltd.

Interest

At CNY 17.75 MM has Grown at 941.99%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at 1.57 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 1.13% and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 4.44%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio